Results 121 to 130 of about 618,162 (164)

ARID5A stabilizes Indoleamine 2,3-dioxygenase expression and enhances CAR T cell exhaustion in colorectal cancer

Translational Oncology
Resistance to chimeric antigen receptor (CAR) T-cell therapy remains a significant challenge in the treatment of solid tumors. This resistance is attributed to various factors, including antigen loss, immunosuppressive tumor microenvironment, and ...
Dandan Wu, Guijun Wang, Shuang Wen, Xian Liu, Qiang He   +4 more
doaj   +1 more source

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

Precision Medical Sciences, Volume 15, Issue 3, Page 206-226, September 2026.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source

Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects in vivo. [PDF]

J Enzyme Inhib Med Chem, 2020
Ge S, Zhong H, Ma X, Zheng Y, Zou Y, Wang F, Wang Y, Hu Y, Li Y, Liu W, Guo W, Xu Q, Lai Y.   +12 more
europepmc   +1 more source

Resolving Endoplasmic Reticulum‐Protein Misfolding Restores Corticosteroid Sensitivity in Experimental Models of Severe Asthma

Allergy, Volume 81, Issue 9, Page 3221-3235, September 2026.
This study investigates the role of ER stress in steroid resistance in severe asthma. Results from advanced 3D models of human bronchial epithelial cells, steroid‐resistant severe asthma mouse models, and human severe asthma sputum samples show that treatment with ICS in combination with the ER stress inhibitor 4‐PBA significantly enhances steroid ...
Prabuddha S. Pathinayake, Alexandra C. Brown, Nikhil T. Awatade, Philip M. Hansbro, Katherine J. Baines, Richard Y. Kim, Nathan W. Bartlett, Jay C. Horvat, Peter A. B. Wark   +8 more
wiley   +1 more source

The Airway Transcriptome in Type 2 Cytokine Biomarker‐High and ‐Low Severe Asthma

Allergy, Volume 81, Issue 9, Page 3300-3317, September 2026.
This study distinguishes severe asthma–related airway transcriptomic changes from the effects of high‐dose ICS. Most dysregulated genes in severe asthma show concordance with corticosteroid responses. Corticosteroid‐resistant T2‐high asthma featured T2‐high and epithelial barrier gene upregulation, while T2‐low asthma featured Th1/IL‐17 signatures. ASM,
Jiashu Shen, Rekha Chaudhuri, Stephen Bicknell, Adel H. Mansur, Rahul Shrimanker, Ian D. Pavord, Stephen J. Fowler, Vanessa Brown, Lorcan P. McGarvey, Peter H. Howarth, Sven‐Erik Dahlén, Ian M. Adcock, Nazanin Zounemat‐Kermani, Joseph R. Arron, Liam G. Heaney, David F. Choy, Timothy S. C. Hinks, Emanuele Marchi, Peter Bradding, on behalf of the UK Medical Research Council Refractory Asthma Stratification programme (RASP‐UK)   +19 more
wiley   +1 more source

GCN2 in proteostasis: structural logic, signalling networks and disease

The FEBS Journal, Volume 293, Issue 18, Page 5627-5644, September 2026.
Threats to protein synthesis activate the kinase GCN2, initiating the integrated stress response (ISR). GCN2 is triggered by stalled ribosomes and uncharged tRNAs, which accumulate when amino acids are scarce. The ISR adjusts cellular physiology by promoting redox balance, protein quality control, and mitochondrial optimisation.
JiaYi Zhu, Stefan J. Marciniak
wiley   +1 more source

Lipophilic Ligand Efficiency-Monitored Discovery of Potent, Achiral, and Bioavailable Apo-IDO1 Inhibitors. [PDF]

ACS Med Chem Lett
Kazmierski WM, Miriyala N, De la Rosa M, Miller J, Gentry ZO, Samano V, Catalano J, Chong PY, Wang F, Price DJ, Basilla J, Mebrahtu M, Wang L, Shewchuk L, Matico R, Dunham R.   +15 more
europepmc   +1 more source

Design, Synthesis, and Structural Evolution of Pseudo-Natural Product IDO1 Inhibitors and Degraders. [PDF]

Angew Chem Int Ed Engl
Cheng XF, Lucas B, Lampe P, Ugel S, Chen S, Unger A, Bischoff M, Adariani SR, Naredla KR, Kumar K, Schmidt A, Strohmann C, Janning P, Gasper R, Lucas M, Gersch M, Sievers S, Bronte V, Ziegler S, Waldmann H.   +19 more
europepmc   +1 more source

Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing

3,3-Disubstituted oxetanes have been utilized as bioisosteres for gem-dimethyl and cyclobutane functionalities. We report the discovery of a novel class of oxetane indole-amine 2,3-dioxygenase (IDO1) inhibitors suitable for Q3W (once every 3 weeks) oral ...
Beata Zamlynny (1417051), Ian Knemeyer (1398904), Nunzio Sciammetta (1290483), Kun Liu (148201), Hua Zhou (50017), David Jonathan Bennett (7456754), Craig Gibeau (1586212), Jude Ferraro (12192189), Theodore A. Martinot (1479601), Charles A. Lesburg (1834624), Abdelghani Achab (2177274), Catherine White (7960844), Jingjun Yin (1493482), Alexander Pasternak (161010), Qinglin Pu (7456739), Elizabeth Freeland (12192183), Hongjun Zhang (1350582), Nicolas Solban (7456751), Brett Hopkins (11291030), Zhiguo J. Song (1831198), Jin Zhai (1618285), Derun Li (1792951), Suzanne DAddio (12192180), Meredeth A. McGowan (1995799), Xavier Fradera (2585029), Huangguang Zhang (12192177), Karin M. Otte (2459014), Stella Vincent (2369365), Indu Bharathan (2125537), J. Richard Miller (1648261), Heidi Ferguson (6337370), Alan Bass (1648318), Bridget Ykoruk (12192186), Ji Qi (49471), Baoqiang Wan (2108638), David L. Sloman (2185060), Yongxin Han (1235268), Catherine Hilliard (2692195), Licheng Song (4440802)   +38 more
core   +1 more source

Boron-Based Functionalities Enhance, the Potency of 2,5-Dimethylfuran-Based IDO1 Inhibitors. [PDF]

Chembiochem
Carraro TJC, Dasgupta S, Ku J, Thomas SR, Rendina LM.   +4 more
europepmc   +1 more source